Ken Griffin Immunome Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$11.54 - $22.11 $77,318 - $148,137	6,700 Added 31.31%	28,100 $340,000
Q1 2024 May 15, 2024	BUY	$11.01 - $27.34 $128,817 - $319,878	11,700 Added 120.62%	21,400 $528,000
Q4 2023 Feb 14, 2024	BUY	$7.3 - $10.73 $29,200 - $42,920	4,000 Added 70.18%	9,700 $103,000
Q3 2023 Nov 14, 2023	SELL	$6.17 - $9.16 $69,721 - $103,508	-11,300 Reduced 66.47%	5,700 $47,000
Q2 2023 Aug 14, 2023	BUY	$4.7 - $7.91 $38,070 - $64,071	8,100 Added 91.01%	17,000 $134,000
Q1 2023 May 15, 2023	BUY	$3.26 - $5.69 $29,013 - $50,641	8,900 New	8,900 $44,000
Q3 2022 Nov 14, 2022	SELL	$3.39 - $6.14 $52,884 - $95,784	-15,600 Reduced 37.05%	26,500 $118,000

115

43.4M

67.2K

65.9K

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $188M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.